

## Supplementary article data

# Hydroxyapatite coating does not improve uncemented stem survival after total hip arthroplasty!

## An analysis of 116,069 THAs in the Nordic Arthroplasty Register Association (NARA) database

Nils P Hailer<sup>1,9</sup>, Stergios Lazarinis<sup>1,9</sup>, Keijo T Mäkelä<sup>2</sup>, Antti Eskelinen<sup>3</sup>, Anne M Fenstad<sup>4</sup>, Geir Hallan<sup>4</sup>, Leif Havelin<sup>4,5</sup>, Søren Overgaard<sup>6,7</sup>, Alma B Pedersen<sup>6,8</sup>, Frank Mehnert<sup>6,8</sup>, and Johan Kärrholm<sup>9</sup>

<sup>1</sup>Department of Orthopaedics, Institute of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden; <sup>2</sup>Department of Orthopaedics and Traumatology, Turku University Hospital, Turku; <sup>3</sup>The Coxa Hospital for Joint Replacement, Tampere, Finland; <sup>4</sup>The Norwegian Arthroplasty Register, Department of Orthopaedic Surgery, Haukeland University Hospital; <sup>5</sup>Department of Clinical Medicine, University of Bergen, Bergen, Norway; <sup>6</sup>The Danish Hip Arthroplasty Register, Center for Clinical Databases, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus; <sup>7</sup>Department of Orthopaedic Surgery and Traumatology and Clinical Institute, Odense University Hospital, Odense; <sup>8</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; <sup>9</sup>Swedish Hip Arthroplasty Register and Department of Orthopaedics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden  
Correspondence: nils.hailer@surgsci.uu.se  
Submitted 2014-03-23. Accepted 2014-05-16

Supplementary Table 4. Sex-, diagnosis-, and age distribution according to country

	Denmark		Norway		Sweden		Finland	
	n	%	n	%	n	%	n	%
Male	17,528	49	7,553	36	11,510	50	17,614	48
Female	17,985	51	13,297	64	11,319	50	19,263	52
Sum	35,513	100	20,850	100	22,829	100	36,877	100
OA	33,505	94	16,369	79	21,296	93	36,315	98
Pediatric	2,008	6	4,481	21	1,533	7	562	2
Sum	35,513	100	20,850	100	22,829	100	36,877	100
<50	2,781	8	2,705	13	3,658	16	2,060	6
50-59	8,056	23	5,725	27	8,528	37	8,836	24
60-74	20,421	58	9,268	44	9,432	41	21,207	58
75>	4,255	12	3,152	15	1,211	5	4,774	13
Sum	35,513	100	20,850	100	22,829	99	36,877	100

Supplementary Table 5. Unadjusted 10-year survival (in %) of stem brands in the Denmark, Norway and Sweden subgroup with stem revision due to aseptic loosening as the endpoint (with 95% confidence intervals and numbers at risk after 10 years). Stems ordered by survival estimates in descending order.

Stem	Survival	2.5% CI	97.5% CI	No. at risk
Cone	99.9	99.6	100.0	158
SCP	99.7	99.3	100.0	189
Bimetric	99.6	99.5	99.7	2,478
Bicontact	99.5	99.1	99.9	167
Corail	99.3	99.1	99.5	1,915
Versys	99.2	98.4	99.9	38
AML	99.1	98.2	99.9	294
CLS	99.0	98.3	99.6	426
ABG	99.0	98.3	99.7	386
Filler	98.7	97.8	99.6	324
Omnifit	96.7	94.4	99.0	144

The 7 stem brands not included in this analysis had fewer than 25 hips at risk after 10-years and were therefore excluded.

Supplementary Table 6. Unadjusted 10-year survival (in %) for the 4 investigated age groups in the Denmark, Norway and Sweden subgroup with stem revision due to aseptic loosening as the endpoint, divided by the presence of HA coating on the stems (with 95% confidence intervals and numbers at risk after 10 years).

Age		Survival	2.5% CI	97.5% CI	No. at risk
< 50	noHA	99.4	99.2	99.6	880
	HA	99.4	99.2	99.6	1,043
50–59	noHA	99.4	99.0	99.9	487
	HA	99.7	99.5	99.9	986
60–74	noHA	99.4	99.2	99.7	1,078
	HA	99.2	98.9	99.4	1,911
≥ 75	noHA	99.4	99.0	99.8	58
	HA	98.4	96.8	100.0	102